Celestica Announces TSX Acceptance of Normal Course Issuer Bid to Repurchase Up to 3.13M Shares

Overview of Filing

On October 30, 2026, Celestica Inc. (NYSE: CLS, TSX: CLS) filed a Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) announcing that the Toronto Stock Exchange (TSX) has accepted its notice to launch a Normal Course Issuer Bid (NCIB).

Key Terms of the Normal Course Issuer Bid

• Maximum Repurchase Amount: Up to 3,132,127 common shares, representing approximately 2.5% of the public float (125,285,094 shares out of 126,111,808 total issued and outstanding common shares as of October 20, 2026).
• Effective Period: Purchases may commence on November 3, 2026, and will expire on November 2, 2027, or earlier if the authorized amount is fully acquired.
• Trading Limitations: Based on average daily trading volume of 436,307 shares on the TSX over the preceding six months, daily purchases on the TSX are capped at 109,076 shares (25% of ADTV), excluding block purchases.
• Trading Facilities: Repurchases may take place on the TSX, the New York Stock Exchange (NYSE), or alternative Canadian trading platforms at prevailing market prices.
• Retirement of Shares: All shares repurchased under the NCIB will be cancelled.
• Automatic Share Purchase Plan (ASPP): Celestica established an ASPP with a designated broker to allow repurchases during customary blackout or restricted periods.

Prior NCIB Activity

• The company's prior NCIB expires on November 2, 2026. Under that program, Celestica had authorization to repurchase up to 5,722,527 shares and completed purchases of 205,184 common shares on the NYSE at a weighted average price of US$271.75 per share through October 20, 2026.

Capital Allocation & Market Implications

• The renewal of the NCIB reflects management's commitment to returning capital to shareholders and reducing share count dilution.
• With funding derived from existing cash resources and credit facility borrowings, the execution pace will likely depend on market conditions, liquidity needs, and share valuation relative to alternative capital deployments.